Uricosuric effect of different doses of irtemazole in normouricaemic subjects
| Autor: | N. Zöllner, Ursula Kronawitter, Ursula Gresser, Irmingard Kamilli |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Pharmacology Uricosuric Dose-Response Relationship Drug business.industry General Medicine Uricosuric Agents medicine.disease Effective dose (pharmacology) Uric Acid Gout chemistry.chemical_compound Dose–response relationship chemistry Pharmacokinetics Oral administration Uricosuric Agent medicine Humans Uric acid Benzimidazoles Pharmacology (medical) business |
| Zdroj: | European Journal of Clinical Pharmacology. 38:489-491 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/bf02336689 |
| Popis: | Irtemazole 12.5 to 50 mg in 6 healthy, normouricaemic subjects caused a maximal decrease in plasma uric acid (after 8 to 12 h) of 46.5%. The uricosuric effect began during the first 60 min after drug administration and it lasted for 7 to 24 h. Renal uric acid excretion returned to its base line value after 8 to 16 h and uric acid clearance after 10.0 to 12.0 h. Doses of irtemazole between 12.5 and 37.5 mg produced a dose-related rise in the uricosuric effect. There was no essential difference between the uricosuric effect of 37.5 mg and 50 mg irtemazole. The D50 dose (that producing a half-maximal effect) was between 16.3 mg and 34.2 mg, (average 24.7 mg). The value of irtemazole in the management of hyperuricaemia and gout remains to be determined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink